CLINICAL_TRIALS
trial_result
· 2020-07-16
Clinical Trial Update: A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) [Phase 1]
Summary
Phase 1 trial assessing pembrolizumab in renal cell cancer was terminated with results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Cell Cancer | Phase 1 | Status: TERMINATED | Results posted: 2020-07-16